DexTech's Phase IIb study for OsteoDex ends with positive follow-up results
The company's randomized Phase IIb study for the treatment of bone metastatic castration-resistant prostate cancer (mCRPC) has now been completed with 2-year follow-up results from the last patients. The primary endpoints of the study concerning markers of bone metabolism have been well achieved. A clear majority of patients showed reduction in their skeletal markers in the blood of the given treatment with OsteoDex. Treatment was very well tolerated (few and mild side effects) and good disease-slowing effect was also seen in the lowest doses. The slowing down and decline of the